- Home
- IBRX vs PRGS Comparison
IBRX vs PRGS Comparison
Compare IBRX & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PRGS
- Stock Information
- Founded
- IBRX 2014
- PRGS 1981
- Country
- IBRX United States
- PRGS United States
- Employees
- IBRX N/A
- PRGS N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PRGS Computer Software: Prepackaged Software
- Sector
- IBRX Health Care
- PRGS Technology
- Exchange
- IBRX Nasdaq
- PRGS Nasdaq
- Market Cap
- IBRX 2.4B
- PRGS 2.4B
- IPO Year
- IBRX N/A
- PRGS 1991
- Fundamental
- Price
- IBRX $2.08
- PRGS $61.09
- Analyst Decision
- IBRX Strong Buy
- PRGS Buy
- Analyst Count
- IBRX 5
- PRGS 7
- Target Price
- IBRX $11.35
- PRGS $73.71
- AVG Volume (30 Days)
- IBRX 8.8M
- PRGS 466.1K
- Earning Date
- IBRX 05-16-2025
- PRGS 06-24-2025
- Dividend Yield
- IBRX N/A
- PRGS 0.57%
- EPS Growth
- IBRX N/A
- PRGS N/A
- EPS
- IBRX N/A
- PRGS 1.27
- Revenue
- IBRX $14,745,000.00
- PRGS $806,739,000.00
- Revenue This Year
- IBRX $579.28
- PRGS $30.62
- Revenue Next Year
- IBRX $179.96
- PRGS $2.94
- P/E Ratio
- IBRX N/A
- PRGS $48.14
- Revenue Growth
- IBRX 2270.58
- PRGS 12.85
- 52 Week Low
- IBRX $1.83
- PRGS $48.00
- 52 Week High
- IBRX $9.16
- PRGS $70.56
- Technical
- Relative Strength Index (RSI)
- IBRX 36.89
- PRGS 64.17
- Support Level
- IBRX $1.83
- PRGS $60.04
- Resistance Level
- IBRX $2.17
- PRGS $62.24
- Average True Range (ATR)
- IBRX 0.18
- PRGS 1.08
- MACD
- IBRX -0.05
- PRGS 0.22
- Stochastic Oscillator
- IBRX 23.56
- PRGS 87.41
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.